Aldeyra Therapeutics Inc. stock ALDX rose 11% Thursday morning, following the announcement of positive results in a late-stage study on a treatment for allergy conjunctivitis. The Lexington-based company reported that the Phase 3 Invigorate-2 trial achieved statistical significance in its primary endpoint as well as all secondary endpoints. The results of INVIGORATE-2 are consistent with those of the Phase 3 INVIGORATE Trial, and with other successful Phase 2 and Phase 3 trials for dry eye disease. This means that reproxalap has the potential to treat this condition.